New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:28 EDTONTYOncothyreon price target raised to $6 from $3 at Stifel
After speaking with a breast cancer physician consultant, Stifel thinks that Oncothyreon's ARRY-380 could be used to treat cancer that has spread from the breast to the central nervous system. The firm thinks that this indication could generate $47M of revenue for the company in 2022, and keeps a Buy rating on the stock.
News For ONTY From The Last 14 Days
Check below for free stories on ONTY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ONTY

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use